Tibremciclib or Placebo Plus Fulvestrant in Hormone Receptor–Positive and ERBB2 -Negative Advanced Breast Cancer After Endocrine Therapy

富维斯特朗 医学 内科学 肿瘤科 耐受性 中止 安慰剂 乳腺癌 危险系数 养生 临床终点 癌症 临床试验 不利影响 雌激素受体 置信区间 病理 替代医学
作者
Zhonghua Tao,Jian Zhang,Qiufan Zheng,Yongsheng Wang,Li Cai,Hongyan Xu,Xinhua Xu,Xiangshun Kong,Sijuan Ding,Chunfang Hao,Hao Wang,Hong Zong,Xin Jin,Xinshuai Wang,Li Yang,Xiuli Yang,Weijie Li,Xiaoya Du,Hui Chen,Pengxiang Wu
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:11 (9): 1055-1055 被引量:5
标识
DOI:10.1001/jamaoncol.2025.2092
摘要

Importance: Cyclin-dependent kinase (CDK) 4/6 inhibitors combined with endocrine therapy (ET) are now considered the standard treatment regimen for hormone receptor-positive (HR+) and ERBB2 (formerly HER2)-negative (ERBB2-) advanced breast cancer (ABC). Tibremciclib (BPI-16350), a novel CDK4/6 inhibitor, has demonstrated favorable tolerability and promising antitumor activity as a monotherapy or combined with fulvestrant among patients with HR+/ERBB2- ABC in a phase 1 trial. Further investigations are necessary to assess the efficacy and safety of tibremciclib. Objective: To compare tibremciclib plus fulvestrant and placebo plus fulvestrant in terms of efficacy and safety among patients with HR+/ERBB2- ABC who exhibited disease progression after ET. Design, Setting, and Participants: The TIFFANY trial was a double-blind, placebo-controlled, phase 3 randomized clinical trial of patients with HR+/ERBB2- ABC who had experienced progression while receiving prior ET and had received no more than 1 line of chemotherapy. This trial was conducted at 69 Chinese centers between May 25, 2022, and April 25, 2023. The data cutoff date for this analysis was March 31, 2024. Interventions: Patients were randomly assigned to receive tibremciclib (400 mg, orally, once daily) plus fulvestrant or placebo plus fulvestrant at a 2:1 ratio until disease progression, death, or treatment discontinuation for various reasons. Main Outcomes and Measures: The primary end point was investigator-assessed progression-free survival (PFS), and the secondary end points included the objective response rate, overall survival, and safety. Results: A total of 274 female patients (median [IQR] age, 53.0 [46.0-60.0] years) were randomly assigned to receive tibremciclib plus fulvestrant (184 [67.2%]) or placebo plus fulvestrant (90 [32.8%]). Among these patients, 144 PFS events occurred (80 in the tibremciclib arm and 64 in the placebo arm), with a median follow-up of 12.9 months for both arms. Tibremciclib plus fulvestrant significantly improved PFS compared with placebo plus fulvestrant (median, 16.5 months [95% CI, 12.8-16.6] vs 5.6 months [95% CI, 4.5-9.2]; hazard ratio, 0.37; 95% CI, 0.27-0.52; P < .001). In patients with measurable disease, tibremciclib plus fulvestrant achieved an objective response rate of 45.6% (95% CI, 37.6%-53.7%) compared with 12.9% (95% CI, 6.1%-23.0%) in the placebo arm (P < .001). The most common grade 3 or higher treatment-emergent adverse events in the tibremciclib vs placebo arm were neutropenia (15.2% vs 5.6%, respectively), anemia (12.0% vs 4.4%, respectively), and hypokalemia (12.0% vs 0%, respectively). No drug-related deaths occurred in the tibremciclib arm, and 1 death occurred in the placebo arm. Conclusions and Relevance: The results of this randomized clinical trial suggest that tibremciclib plus fulvestrant was associated with statistically significant and clinically meaningful improvements in PFS compared with placebo plus fulvestrant. Furthermore, tibremciclib plus fulvestrant demonstrated a manageable safety profile in patients with HR+/ERBB2- ABC who experienced progression while receiving prior ET. Trial Registration: ClinicalTrials.gov Identifier: NCT05433480.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
RAN18完成签到,获得积分10
1秒前
清爽的莆完成签到 ,获得积分10
1秒前
豆豆豆豆完成签到,获得积分10
2秒前
daomaihu发布了新的文献求助100
2秒前
荼蘼发布了新的文献求助10
2秒前
4645发布了新的文献求助10
2秒前
3秒前
Maestro_S的应助被zone采纳,获得10
3秒前
廖玲丽完成签到 ,获得积分10
4秒前
4秒前
5秒前
tang发布了新的文献求助10
5秒前
5秒前
milion完成签到,获得积分10
5秒前
star完成签到,获得积分10
5秒前
7秒前
易怀亮完成签到,获得积分10
7秒前
Luxi发布了新的文献求助10
7秒前
7秒前
7秒前
Z_Z完成签到,获得积分0
7秒前
cs完成签到,获得积分10
8秒前
tutu发布了新的文献求助10
8秒前
万物更始完成签到,获得积分10
8秒前
在水一方的应助被Eli采纳,获得10
9秒前
Ning完成签到,获得积分10
9秒前
ket的应助被zx采纳,获得10
9秒前
asd2221完成签到,获得积分20
10秒前
GamAooL发布了新的文献求助30
10秒前
sttise发布了新的文献求助10
10秒前
Dzzz完成签到,获得积分10
10秒前
11秒前
荼蘼发布了新的文献求助10
11秒前
小二郎的应助被科研通管家采纳,获得10
11秒前
刘国建完成签到 ,获得积分10
11秒前
Maestro_S的应助被科研通管家采纳,获得10
11秒前
赘婿的应助被科研通管家采纳,获得10
11秒前
Lucas的应助被科研通管家采纳,获得10
12秒前
在水一方的应助被科研通管家采纳,获得10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175157
求助须知:如何正确求助?哪些是违规求助? 9566975
关于积分的说明 21789458
捐赠科研通 7769647
什么是DOI,文献DOI怎么找? 3431836
关于科研通互助平台的介绍 2556078
邀请新用户注册赠送积分活动 2477241